Objective-Ischemia caused by narrowing of femoral artery is a major cause of peripheral arterial disease and morbidity affecting patients with diabetes mellitus. We have previously reported that the inhibition of the angiogenic response to VEGF (vascular endothelial growth factor) in diabetic mice was associated with the increased expression of SHP-1 (SH2 domain-containing phosphatase 1), a protein that can be activated by the AT2 (angiotensin II type 2) receptor. Deletion of AT2 receptor has been shown to promote angiogenesis within the ischemic muscle. However, the relative impact of AT2 receptor in diabetic condition remains unknown. Approach and Results-Nondiabetic and diabetic AT2 null (Atgr2 −/Y ) mice underwent femoral artery ligation after 2 months of diabetes mellitus. Blood perfusion was measured every week ≤4 weeks post-surgery. Expression of the VEGF, SHP-1, and renin-angiotensin pathways was evaluated. Blood flow in the ischemic muscle of diabetic Atgr2 −/Y mice recovered faster and ≤80% after 4 weeks compared with 51% recovery in diabetic control littermates. Diabetic Atgr2 −/Y had reduced apoptotic endothelial cells and elevated small vessel formation compared with diabetic Atgr2 +/Y mice, as well as increased SHP-1 expression and reduced VEGF receptor activity. In endothelial cells, high glucose levels and AT2 agonist treatment did not change SHP-1, VEGF, and VEGF receptor expression. However, the activity of SHP-1 and its association with the VEGF receptors were increased, causing inhibition of the VEGF action in endothelial cell proliferation and migration. Conclusions-Our results suggest that the deletion of AT2 receptor reduced SHP-1 activity and restored VEGF actions, leading to an increased blood flow reperfusion after ischemia in diabetes mellitus. Visual Overview-An online visual overview is available for this article. 
P eripheral artery disease is a severe and prevalent complication of diabetes mellitus. Among diabetic patients aged over 75 years and suffering from this vascular disease, more than half will die within 5 years. 1 Diabetic patients affected with peripheral artery disease are usually characterized by a decreased blood flow in the lower extremities resulting from occluded arteries. Because of diabetes mellitus-induced insufficient collateral vessel formation, this disease often leads to ulcer formation and eventually amputation. 2 Multiple evidences pointed toward an abnormal angiogenic response to ischemia in diabetes mellitus, which involves different vascular cell types and growth factors. 3 VEGF (vascular endothelial growth factor) plays a major role in the process known as angiogenesis. 4 By binding to its tyrosine kinase receptors, it permits the activation of several pathways, leading to multiple cellular effects. 5 In particular, VEGF stimulation promotes cell permeability, migration, and proliferation, all of which are essential to collateral vessel formation. The importance of VEGF in ischemia-induced angiogenesis has been demonstrated in several studies in a nondiabetic setting. 6, 7 In contrast, the poor collateral vessel formation in diabetes mellitus-induced ischemia is linked to the lack of action of multiple growth factors, including VEGF. 8 In addition to reduced VEGF actions by hyperglycemia, previous studies have demonstrated that diabetes mellitus caused bone marrow-derived progenitor cell dysfunction 9, 10 and reduction of extracellular matrix degradation by metalloproteinases, 11 which contributed to poor neovascularization. Despite the presence of oxidative stress, a major regulator of VEGF, VEGF levels are reduced in peripheral muscle of diabetic rodents. 12 Experiments to improve angiogenesis and vascular cell survival by therapeutic agent and system delivery of VEGF by increasing its expression have been reported in nondiabetic animal models. 13, 14 However, to date, the clinical December 2017 benefits of VEGF administration have been limited. 15, 16 Thus, the underlying mechanisms of reduced VEGF expression in diabetic peripheral artery disease remain unresolved. Our group has previously reported that diabetes mellitus caused the activation of the PKC (protein kinase C) delta, leading to the reduction of VEGF receptor activity and lower blood reperfusion in ischemic muscle. 17 The inhibition of the VEGF receptor tyrosine phosphorylation was associated with an elevated expression of SHP-1 (SH2 domain-containing phosphatase 1).
Others pathways are known to play a role in ischemiainduced angiogenesis, notably the angiotensin II (Ang II) receptors pathway. 18 Activation of the renin angiotensin system (RAS) has been shown to promote some of the metabolic syndrome risk factors, including insulin resistance and hyperglycemia. 19 Inhibition of RAS (with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers) is used to treat several conditions such as high blood pressure, heart failure, and kidney damage associated with diabetes mellitus. 20 In the recent years, RAS inhibitors have been proposed to reduce the risk of developing type 2 diabetes mellitus in high-risk populations. 21 Although RAS is typically known to play a role in blood pressure regulation, it is now established that it can act locally in many tissues, leading to diverse effects depending on which Ang II receptor is activated. AT1R (angiotensin type I receptor) is believed to be the major effector after RAS activation. However, opposing actions can be obtained via stimulation of the AT2R (angiotensin II type 2 receptor), which may play an antagonizing role. One of the many biological processes involving Ang II receptors is angiogenesis. Although AT1R seems to promote angiogenesis, 22 AT2R activation has antiangiogenic properties. 23 Silvestre et al 24 demonstrated that the AT2R negatively regulated ischemia-induced angiogenesis. However, to our knowledge, there is no study that investigated the role of AT2R during blood flow recovery after surgery-induced hindlimb ischemia in a context of diabetes mellitus. In addition, previous studies demonstrated the capacity of AT2R to interact with SHP-1 in rat fetal tissues. 25 Therefore, we hypothesized that AT2R activation may play a role in diabetes mellitus-triggered abnormal angiogenic response through activation of SHP-1.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement. Figure 1C Collateral vessel formation, a normal response to occlusion of a large artery, is seriously impaired in patients with diabetes mellitus, rendering the tissue downstream more prone to critical ischemia. Because the diabetic Atgr2
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showed greater improvement of lower limb blood flow reperfusion after ischemia, we have assessed vascular density and capillary formation in the ischemic adductor muscles. Histological analysis indicated that adductor muscles of diabetic Atgr2 +/Y mice exhibited a significant 39% (P=0.0448) vascular density reduction as compared with nondiabetic Atgr2 +/Y mice, a phenomenon that was not observed in the diabetic Atgr2 −/Y mice ( Figure 2A and 2B). To evaluate the proportion of small vessel density, the diameter of vessels of 50 μm or less was considered as capillaries. Thus, the deterioration of the capillary density in diabetic Atgr2 +/Y mice was associated with a significant 57% reduction in number of small vessels ( Figure 2C . These data suggest that the AT2 receptors did not influence the expression of VEGF and its receptor in diabetes mellitus. We have previously shown that the tyrosine phosphorylation of the VEGFR2 was reduced in diabetic mice. 17 We have replicated our previous finding showing that the phosphorylation of VEGFR2 was significantly decreased in diabetic Atgr2 
Expression of SHP-1 Is Prevented in Absence of the AT2 Receptor
The phosphorylation of specific tyrosine residues within the receptor tyrosine kinase, such as VEGFR2, creates binding sites for phosphotyrosine-binding domain-and SH2 (Src homology 2) domain-containing protein. These domains can recruit specific proteins that either activate downstream signals (Src and phospholipase C) or downregulate receptor tyrosine kinase, including the protein tyrosine phosphatase. We have previously showed that diabetes mellitus-induced inhibition of VEGFR2 in ischemic muscles was associated with an increased expression of SHP-1. 17 These observations were confirmed in our study demonstrating that SHP-1 mRNA ( Figure 4A ) and protein ( Figure 4B ) expression were upregulated in ischemic adductor muscles of diabetic Atgr2 +/Y mice, without affecting SHP-2 or VEPTP (vascular endothelial protein tyrosine phosphatase) expression ( Figure 4B and 4C). In contrast, diabetic Atgr2 +/Y mice did not exhibit elevated SHP-1 mRNA and protein levels, suggesting that enhanced expression of SHP-1 can be regulated by the activation of the AT2 receptor in diabetes mellitus. Furthermore, the increased expression of SHP-1 in diabetic ischemic muscle enhanced its interaction with the VEGFR2 and reduced VEGFR2 tyrosine phosphorylation, which was not observed in diabetic Atgr2 −/Y mice ( Figure 4E ). These data suggest that AT2R regulates SHP-1 activity and interaction with VEGFR2 in diabetic ischemic muscle.
High Glucose Exposure and AT2 Activation Lead to Endothelial Cell Proliferation and Migration Inhibition
To explain how diabetes mellitus and activation of the AT2 receptor reduced proangiogenenic actions of VEGF on endothelial cell capacity to proliferate and migrate, we have performed in vitro cell count and migration scratch assays using the AT2 receptor agonist CGP42112A and antagonist PD123319. As expected, stimulation of endothelial cells with VEGF-A (25 ng/mL) for 24 hours promoted cell proliferation in normal glucose levels ( Figure 5A ). Cells exposed to high glucose levels (25 mmol/L) or treated with CGP42112A (10 nmol/L) alone completely prevented VEGF-induced endothelial cell proliferation ( Figure 5A ). In contrast, treating endothelial cells with PD123319 (10 umol/L) during high glucose exposure restored VEGF-induced cell proliferation ( Figure 5A ). Migration is another important process involved in angiogenesis. Using Ibidi's insert to create equal separation between cells (500 μm) in each experiment, the treatment with VEGF in normal glucose concentration promoted endothelial cell migration from 25% of the surface occupied by the endothelial cells to 57% of the surface area ( Figure 5B and 5C ). Exposing cells to high glucose concentrations for 24 hours reduced VEGF effect on cell migration with only 35% of the surface area. Interestingly, the AT2 agonist was as potent as high glucose level treatment of decreasing VEGF action on endothelial cell migration ( Figure 5B and 5C ). No additive effect was noted when cells were exposed to high glucose levels in presence of the CGP42112A.
High Glucose and AT2 Agonist Reduced VEGF Signaling Pathway Through SHP-1 Activity on the VEGF Receptor VEGF stimulation induces Akt phosphorylation as the main signaling pathway of VEGF-induced cell migration and survival. Therefore, we have evaluated the Akt signaling pathway on VEGF stimulation. As shown in Figure 6A , VEGF raised Akt phosphorylation by more than 3-fold, an effect that was reduced by 45% and 64% in endothelial cells exposed to CGP42112A alone or high glucose levels for 24 hours, respectively. The combined treatment (high glucose concentrations and CGP42112A) completely blunted VEGF-stimulated Akt phosphorylation ( Figure 6A ). In contrast, treating endothelial cells with the AT2R antagonist enhanced VEGF-induced Y1059 and Y1175 of VEGFR2, as well as Akt phosphorylation in both normal and high glucose concentrations ( Figure 6B ). Since our in vivo data demonstrated that diabetes mellitus increased SHP-1 expression in ischemic muscle, we have assessed the expression of SHP-1 in endothelial cells after exposure to high glucose concentrations and AT2 activation. Surprisingly, neither high glucose level exposure and CGP42112A treatment influenced the expression of SHP-1 and SHP-2 in endothelial cells ( Figure 6C) . However, the measurement of the phosphatase activity of SHP-1 was significantly increased by 2-fold and 2.5-fold in endothelial cells treated with the CGP42112A and exposed to high glucose levels, respectively ( Figure 6D ). Interestingly, elevated SHP-1 activity by either CGP42112A and HG levels was associated to increase interaction of SHP-1 with the VEGFR2 receptor in coimmunoprecipitation assays ( Figure 6E ). In contrast, increased interaction of SHP-1 with VEGFR2 in endothelial cells exposed to high glucose levels was abrogated with the AT2R antagonist treatment ( Figure 6F ). 
Discussion
The activation of the RAS is recognized to be an important contributing factor of the development and progression of vascular pathology in diabetes mellitus. Inhibition of the activity of Ang II, the main mediator of the RAS, with pharmacological inhibitors such as angiotensin receptor blockers and angiotensin-converting enzyme inhibitors are the main treatment for patients with diabetes mellitus and renal/cardiac disease. 20 Of the 2 major receptors of the Ang II, AT2R is widely and abundantly expressed in fetal tissue, 26 declining after birth. Despite some functional evidence that AT2R is present in adult vasculature, the majority of studies have focused on AT2R during pathophysiological conditions. 27 Our study provided evidence that AT2R activation is involved in diabetes mellitus-induced poor collateral vessel formation after ischemia. Activation of ATR2 resulted in the reduction of endothelial cell proliferation and migration because of the enhanced phosphatase activity of SHP-1 that reduced the proangiogenic actions of VEGF in endothelial cells.
A previous study reported that AT2R induced antiangiogenic effects in mice after hindlimb ischemia with or without Ang II infusion. 24 Our results in nondiabetic Atgr2 −/Y mice corroborated these findings showing that the absence of AT2R favored neovascularization and blood flow reperfusion. Dysfunction of vessel regeneration during ischemia is a characteristic of people with diabetes mellitus, which can ultimately affect the development, severity, and outcomes of foot ulcerations, including infection, and other common comorbidities. Interestingly, diabetes mellitus-induced poor collateral vessel formation was completely abolished in diabetic Atgr2 −/Y mice, indicating that AT2R activation could play an important role on high glucose level inhibitory effects on angiogenesis. The absence of the AT2R in diabetic mice promoted the formation of new small vessel (<50 μm) as compared with the diabetic Atgr2 +/Y mice. It is also interesting to note that diabetes mellitus raised AT1R expression, known to favor angiogenesis, but not the AT2R, angiotensin-converting enzyme 1, and angiotensinconverting enzyme 2 in ischemic adductor muscle that was prevented in diabetic Atgr2 −/Y mice ( Figure IIA through IID in the online-only Data Supplement). Although 4 weeks evaluation of blood flow reperfusion is commonly used in mouse model of hindlimb ischemia, acute limb ischemia, defined as any sudden reduction in leg perfusion because of thrombosis and embolism, is a clinical threat to limb viability. Therefore, additional experiments will be required to determine whether AT2 receptor activation can be beneficial during acute limb ischemia.
Probably, the most important player in new vessel formation are the blood vessel lining endothelial cells. It is well established that high glucose levels drastically change endothelial cell metabolism and cause its dysfunction. AT2R is also capable of regulating a class of genes involved in endothelial cell migration and growth-inhibiting factors. 28 Under hypoxia, Ang II promoted endothelial sprout formation, a response that was blocked by AT2R antagonist PD123319 but not the losartan, an AT1R inhibitor. 29 However, previous publications provided conflicting data for the role of AT2R in endothelial cell proliferation and apoptosis. Benndorf et al 30 demonstrated that the activation of the AT2R caused inhibition of VEGF-induced endothelial cell migration and tubule formation. Another study showed that AT2R activation reduced endothelial cell migration by enhancing integrin β like-1 expression that has been associated with the attachment of endothelial cell to the extracellular matrix. 31 In contrast, in a retinal angiogenesis, blockage of AT2R using the PD123319 reduced retinal endothelial cell growth. 32 Furthermore, AT2R activation with C21, a selective agonist, induced the upregulatin of VEGF through the stimulation of the Akt/mTOR (mammalian target of rapamycin) signaling pathway in ischemic neurones. 33 In our study, the absence of AT2R reduced endothelial cell undergo apoptosis after ischemia in a context of diabetes mellitus. Furthermore, both high glucose level exposure and treatment of AT2R agonist prevented VEGF-induced VEGFR2 and Akt phosphorylation, as well as endothelial cell proliferation and migration, whereas treatment with PD123319 enhanced VEGF actions. Overall, these data suggest that the activation of AT2R may generate diverse responses depending on the endothelial cell localization and milieu. Interestingly, a recent elegant study using the crystal structure of the human AT2R showed that the noncanonical position of the helix VIII prevented the recruitment of G-couple proteins or β-arrestins, providing new insight on designing better selective ligands of the angiotensin receptors. 34 The activation of both SH2-domain protein phosphatase SHP-1 and SHP-2 is considered to be a critical downstream effect of Ang II stimulation. 35, 36 It has been reported that Ang II stimulation generated opposite effects through the activation of AT1R and AT2R. Previous studies have demonstrated in vascular smooth muscle cells that Ang II stimulation activated ERK and Pyk kinase through AT1R-promoting cell survival, whereas AT2R/SHP-1 phosphatase activity attenuated this process. 37, 38 Sohn et al 39 indicated that the stimulation of AT2 increased tyrosine phosphatase activity in human umbilical vein endothelial cells. Our data suggest that both high glucose exposure and activation of AT2R induced SHP-1 phosphatase activity and interaction with VEGFR2 that caused the inhibition of VEGF proangiogenic effects on cell proliferation and migration. Interestingly, in vivo data showed that diabetes mellitus-increased binding of SHP-1 with VEGFR2 reduced VEGFR2 phosphorylation in ischemic muscle that was partially prevented in diabetic Atgr2 −/Y mice, suggesting that AT2R activation is not the solo pathway that decreased VEGFR2 activity in diabetes mellitus. Another study reported that SHP-2 phosphatase activity is necessary for Ang II-induced degradation of Bcl-xl, causing cell apoptosis. 40 However, in our study, we did not observe change in SHP-2 expression, phosphatase activity, and interaction with VEGFR2.
The focus of this article was on AT2R actions on endothelial cell function. Interestingly, in contrast to our in vivo findings, cultured cell data indicated that hyperglycemia and AT2R activation did not change the expression of SHP-1. Therefore, we cannot exclude the possibility that the absence of AT2R in smooth muscle cells may have contributed to the blood flow recovery in diabetic Atgr2 −/Y mice. Although no consensus has been reached on the biological consequence of AT2R activation, previous studies have reported that AT2R exerts antigrowth and proapoptotic effects in vascular smooth muscle cells in vitro and in vivo. 41, 42 Furthermore, other studies have demonstrated that AT2R stimulation increased the formation of the SHP-1/ATIP complex, leading to its translocation to the nucleus, which caused inhibition of smooth muscle cell proliferation, inflammation, and oxidative stress in femoral artery after cuff placement. 43, 44 Thus, the deletion of AT2R in smooth muscle cells may have participated to vessel maturity and stability because of the proliferation of smooth muscle cells. In addition, we cannot ignore the potential impact of AT2R activation on bone marrow-derived progenitor cell function. Previous study demonstrated that Ang II can induce epicardial progenitor cell differentiation into smooth muscle cells. 45 However, further experiments will be required to investigate the effects of AT2R activation in smooth muscle cells, as well as in endothelial progenitor cell function in the context of diabetes mellitus.
In conclusion, our article provided evidence that the AT2 receptor in diabetes mellitus promoted the activity of SHP-1, which was associated with the VEGF receptor, inhibition of VEGF actions on endothelial angiogenesis, and poor collateral vessel formation.
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